IL160649A0 - Methods for inhibiting cognitive deterioration in adults with down syndrome - Google Patents
Methods for inhibiting cognitive deterioration in adults with down syndromeInfo
- Publication number
- IL160649A0 IL160649A0 IL16064902A IL16064902A IL160649A0 IL 160649 A0 IL160649 A0 IL 160649A0 IL 16064902 A IL16064902 A IL 16064902A IL 16064902 A IL16064902 A IL 16064902A IL 160649 A0 IL160649 A0 IL 160649A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- adults
- cognitive deterioration
- receptor antagonist
- glucocorticoid receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Toilet Supplies (AREA)
- Casting Support Devices, Ladles, And Melt Control Thereby (AREA)
- Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31665301P | 2001-08-31 | 2001-08-31 | |
PCT/US2002/027576 WO2003020216A1 (en) | 2001-08-31 | 2002-08-27 | Methods for inhibiting cognitive deterioration in adults with down's syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
IL160649A0 true IL160649A0 (en) | 2004-07-25 |
Family
ID=23230024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16064902A IL160649A0 (en) | 2001-08-31 | 2002-08-27 | Methods for inhibiting cognitive deterioration in adults with down syndrome |
Country Status (16)
Country | Link |
---|---|
US (1) | US7402578B2 (no) |
EP (1) | EP1432379B1 (no) |
JP (2) | JP2005501882A (no) |
KR (1) | KR20040029116A (no) |
CN (2) | CN1868480A (no) |
AT (1) | ATE411013T1 (no) |
CA (1) | CA2459033C (no) |
DE (1) | DE60229411D1 (no) |
ES (1) | ES2314103T3 (no) |
HK (1) | HK1062533A1 (no) |
IL (1) | IL160649A0 (no) |
MX (1) | MXPA04001893A (no) |
NO (1) | NO332723B1 (no) |
NZ (1) | NZ531477A (no) |
WO (1) | WO2003020216A1 (no) |
ZA (1) | ZA200401754B (no) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL161248A0 (en) * | 2001-10-26 | 2004-09-27 | Akzo Nobel Nv | USE OF (11beta,17beta)-11-(1,3-BENZODIOXOL-5-YL) 17-HYDROXY-17-(1-PROPYNYL)-ESTRA-4,9-DIEN-3-ONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER |
MX2009008284A (es) | 2007-02-02 | 2009-08-12 | Pfizer Prod Inc | Compuestos triciclicos y su uso como moduladores de receptor de glucocorticoides. |
EP2306830A4 (en) * | 2008-07-01 | 2012-06-06 | Corcept Therapeutics Inc | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS |
US11103514B2 (en) * | 2010-05-26 | 2021-08-31 | Corcept Therapeutics, Inc. | Treatment of muscular dystrophy |
US10500216B2 (en) | 2011-11-18 | 2019-12-10 | Corcept Therapeutics, Inc. | Optimizing mifepristone absorption |
US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
US9457141B2 (en) | 2013-06-03 | 2016-10-04 | Bigfoot Biomedical, Inc. | Infusion pump system and method |
US9943526B2 (en) | 2015-04-21 | 2018-04-17 | Corcept Therapeutics, Inc. | Optimizing mifepristone levels for cushing's patients |
CA3121193C (en) | 2018-12-19 | 2024-03-12 | Corcept Therapeutics Incorporated | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6141798A (en) * | 1997-02-05 | 1998-08-25 | Pharm-Eco Laboratories, Incorporated | Drugs for memory enhancement |
CN1528315A (zh) * | 1997-10-06 | 2004-09-15 | ������˹̹�������ѧ�й�ίԱ�� | 治疗糖皮质素功能失调相关性精神病的方法 |
IL139672A (en) * | 1998-05-15 | 2005-11-20 | Univ Leland Stanford Junior | Glucocorticoid receptor antagonists for the tretment of dementia |
US6620802B1 (en) * | 1999-11-23 | 2003-09-16 | Corcept Therapeutics, Inc. | Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist |
US20020065259A1 (en) * | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
CN1853722A (zh) * | 2001-07-23 | 2006-11-01 | 科塞普特治疗公司 | 预防由抗精神病药物引起的体重增加的方法 |
-
2002
- 2002-08-27 MX MXPA04001893A patent/MXPA04001893A/es active IP Right Grant
- 2002-08-27 DE DE60229411T patent/DE60229411D1/de not_active Expired - Lifetime
- 2002-08-27 ES ES02770441T patent/ES2314103T3/es not_active Expired - Lifetime
- 2002-08-27 CN CNA200510132945XA patent/CN1868480A/zh active Pending
- 2002-08-27 IL IL16064902A patent/IL160649A0/xx not_active IP Right Cessation
- 2002-08-27 CA CA2459033A patent/CA2459033C/en not_active Expired - Fee Related
- 2002-08-27 EP EP02770441A patent/EP1432379B1/en not_active Expired - Lifetime
- 2002-08-27 JP JP2003524530A patent/JP2005501882A/ja active Pending
- 2002-08-27 CN CNA028186087A patent/CN1556708A/zh active Pending
- 2002-08-27 WO PCT/US2002/027576 patent/WO2003020216A1/en active IP Right Grant
- 2002-08-27 KR KR10-2004-7003036A patent/KR20040029116A/ko not_active Application Discontinuation
- 2002-08-27 AT AT02770441T patent/ATE411013T1/de not_active IP Right Cessation
- 2002-08-27 NZ NZ531477A patent/NZ531477A/en not_active IP Right Cessation
- 2002-08-28 US US10/230,575 patent/US7402578B2/en not_active Expired - Lifetime
-
2004
- 2004-03-03 ZA ZA2004/01754A patent/ZA200401754B/en unknown
- 2004-03-31 NO NO20041338A patent/NO332723B1/no not_active IP Right Cessation
- 2004-07-26 HK HK04105488A patent/HK1062533A1/xx not_active IP Right Cessation
-
2008
- 2008-12-08 JP JP2008312752A patent/JP2009102343A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2459033C (en) | 2012-05-22 |
EP1432379A1 (en) | 2004-06-30 |
NO20041338D0 (no) | 2004-03-31 |
US7402578B2 (en) | 2008-07-22 |
JP2009102343A (ja) | 2009-05-14 |
KR20040029116A (ko) | 2004-04-03 |
CN1868480A (zh) | 2006-11-29 |
WO2003020216A1 (en) | 2003-03-13 |
ZA200401754B (en) | 2005-05-25 |
NO20041338L (no) | 2004-05-28 |
EP1432379B1 (en) | 2008-10-15 |
NO332723B1 (no) | 2012-12-27 |
ATE411013T1 (de) | 2008-10-15 |
DE60229411D1 (de) | 2008-11-27 |
MXPA04001893A (es) | 2005-03-07 |
CN1556708A (zh) | 2004-12-22 |
CA2459033A1 (en) | 2003-03-13 |
HK1062533A1 (en) | 2004-11-12 |
EP1432379A4 (en) | 2005-07-13 |
US20030064974A1 (en) | 2003-04-03 |
NZ531477A (en) | 2006-10-27 |
JP2005501882A (ja) | 2005-01-20 |
ES2314103T3 (es) | 2009-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108562T1 (el) | Μεθοδοι για την προληψη προσληψης βαρους η οποια προκαλειται απο αντιψυχωτικες θεραπειες | |
IL139672A0 (en) | Glucocorticoid receptor antagonists for the treatment of dementia | |
CA2302586A1 (en) | Methods for treating psychosis associated with glucocorticoid related dysfunction | |
WO2002076390A3 (en) | Methods for treating stress disorders using glucocorticoid receptor-specific antagonists | |
NO20003550D0 (no) | Farmasøytiske sammensetninger og anvendelse herav | |
PT2990420T (pt) | Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos | |
IL166405A0 (en) | 3-z-Ä1-4-(n-((4-methyl-piperazin-1-yl)methylcarbonyl)-n-methyl-aminoanilo)-1-phenyl-methyleneÜ-6-methyxycarbonyl-2-indoline-monoethanesulphonate and the use thereof as a pharmaceutical composition | |
WO2004058717A8 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
MXPA03000458A (es) | Ligandos receptores de capsaicina. | |
TR200301613T2 (tr) | Sapogenin türevleri, bunların sentezi ve kullanımı, bunların kullanım metotları. | |
IL142047A0 (en) | Mglur5 antagonists for the treatment of pain and anxiety | |
IL160649A0 (en) | Methods for inhibiting cognitive deterioration in adults with down syndrome | |
DK0712311T3 (da) | Antiglucocorticoidsteroider til behandling af angstlidelser | |
MXPA01008993A (es) | Tratamiento de combinacion para depresion y ansiedad. | |
HUP0200707A3 (en) | N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists pharmaceutical compositions containing them and their use | |
WO2004069202A3 (en) | Antiglucocorticoids for the treatment of postpartum psychosis | |
HK1059036A1 (en) | Use of glucocorticoid receptor-specific antagonists for the treatment of delirium | |
AU2002219192A1 (en) | Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect | |
IL149357A0 (en) | Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents | |
EP1726307A3 (en) | Methods for treating psychosis associated with glucocorticoid related dysfunction | |
GB2377176B (en) | Devices for administering material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |